| Drug Name |
Peramivir |
| Drug ID |
BADD_D01732 |
| Description |
Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days. |
| Indications and Usage |
Indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.[label] |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AH03 |
| DrugBank ID |
DB06614
|
| KEGG ID |
D03829
|
| MeSH ID |
C414210
|
| PubChem ID |
154234
|
| TTD Drug ID |
D0P2IW
|
| NDC Product Code |
63552-077; 72769-181; 58159-052; 0792-0636 |
| UNII |
QW7Y7ZR15U
|
| Synonyms |
peramivir | (1S,2S,3R,4R)-3-((1S)-1-acetamido-2-ethylbutyl)-4-((amino(imino)methyl)amino)-2-hydroxycyclopentanecarboxylic acid trihydrate | peramivir trihydrate | 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid | BCX 1812 | BCX1812 | BCX-1812 | RWJ 270201 | RWJ270201 | RWJ-270201 | Rapivab |
